Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from SEC filings.
GoodRx Holdings, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-66.4% vs price
Base Case (Median)
-28.2% vs price
Bull Case (75th pct.)
43.0% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $1.15 | -67.2% | High (40%) |
| PE Comparable | $1.02 | -71.0% | Medium (25%) |
| Growth Trajectory DCF | $3.77 | 7.4% | Medium (20%) |
| Graham Number | $1.28 | -63.6% | Low (10%) |
| EV/EBITDA | $5.43 | 54.8% | Medium (20%) |
| EV/FCF | $11.62 | 231.0% | Medium (20%) |
Based on 6 out of 8 methods, GDRX appears fairly valued at the current price of $3.51. The base case fair value of $2.52 implies 28.2% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.
